Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Imagine Being As Clueless As Scotty And Not Owning Lots Of Pluri !
Man, He Sure Is As Clueless As They Come !!!
Nice....Pluri Biotech- United States Patent For Non-Diabetic CLI & IC Patients
Which Is 20 to 40 % of ALL CLI Patients !!!
Note: The Patent Also Has A Digital App For Patients & Providers !!! Awesome !!!
https://patentscope.wipo.int/search/en/detail.jsf?docId=US438195758&_cid=P11-M0V2TK-99057-1
September Company Presentation:
https://pluri-biotech.com/presentation/
The Future of Cell-Based Products with Yaky Yanay, CEO of Pluri
Believer Meats Study is “First” Demonstration of Cost-Efficient Manufacturing of Cultivated Meat
https://cultivated-x.com/meat/study-continuous-manufacturing-cultivated-meat-significantly-reduce-costs/
Yaky Yanay, Pluri President & CEO will be presenting the Pluri story at 10.30am ET virtually on August 20, 2024.
Register To View Webcast
https://www.webcaster4.com/Webcast/Page/3062/51171
Stirring the pot: Bioreactor breakthroughs
https://www.thecellbase.com/news/stirring-the-pot-bioreactor-breakthroughs
New Tutes !!!
August 14th-UBS-- 10,167 Shares
August 15th-Jane Street-- 8,396 Share
Coffee Without Beans !!!
https://vegconomist.com/plant-cell-cultivation/companies-making-plants-cells/
Abstract: Placental-derived stromal-like cells (PLX-PAD) have been shown to facilitate muscle tissue recovery after injury and stimulate angiogenesis.
https://onlinelibrary.wiley.com/doi/full/10.1002/smsc.202400228
Kadimastem taps Pluri to produce therapeutic cells for ALS and diabetes
https://www.bioprocessintl.com/deal-making/kadimastem-taps-pluri-to-produce-therapeutic-cells-for-als-and-diabetes
Pluri’s CDMO arm takes on ALS and diabetes in cell therapy deal
https://www.biopharma-reporter.com/Article/2024/07/23/Pluri-CDMO-lands-ALS-and-diabetes-cell-therapy-deal?int_campaign=Related-News&int_campaign_type=Right_column
Pluri’s CDMO to Manufacture Kadimastem’s Cell Therapy Candidates
https://www.contractpharma.com/contents/view_breaking-news/2024-07-18/pluris-cdmo-to-manufacture-kadimastems-cell-therapy-candidates/
Pluri’s CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product Candidates
https://pluri-biotech.com/releases/pluris-cdmo-selected-to-manufacture-kadimastems-novel-cell-therapy-product-candidates/
“By combining advanced cell expansion technology with the unique attributes of MAIT cells, Pluri is on the brink of delivering off-the-shelf solutions with unmatched consistency,” said Dr. Richard L. Kendall.
Dr. Kendall, Ph.D, is Chief Science Officer of Catena Bio, a company whose technology enables them to synthesize novel biomolecules in any structure, combination, or orientation. Previously, Dr. Kendall was the President and CEO of ImmPACT BIO, a cell therapy company developing engineered T cells for the treatment of cancer. Notably, Dr. Kendall also held significant positions at leading biopharmaceutical companies, serving as Vice President of Research at Kite Pharma, where he was responsible for the company’s research pipeline and development of CAR-T technologies, as well as Executive Director and Head of Oncology Research at Amgen.
https://drug-dev.com/pluri-launches-novel-immunotherapy-platform-for-solid-tumor-treatment/
If Pluri's CAR-Mait Cells Are Able To Treat Solid Tumors? It Will Become One Of The Most Important Advances In The History of Oncology !!!
Off the Shelf Platform: Efrat Kaduri from Pluri Inc. In a Riveting Conversation with PharmaShots
https://www.pharmashots.com/18344/off-the-shelf-platform-efrat-kaduri-from-pluri-inc-in-a-riveting-conversation-with-pharmashots
July Company Presentation:
https://pluri-biotech.com/wp-content/uploads/2024/07/Pluri-PPT-investor_Q2_July_2024-final.pdf
Pluri Announces €1 Million Proof of Concept Agreement to Enhance Global Sustainable Vegetable Supply
https://www.streetinsider.com/Globe+Newswire/Pluri+Announces+%E2%82%AC1+Million+Proof+of+Concept+Agreement+to+Enhance+Global+Sustainable+Vegetable+Supply/23438713.html
"Don’t write off cultivated meat just yet, says Ever After Foods: ‘We’re not offering incremental improvements but something truly disruptive."
https://agfundernews.com/dont-write-off-cultivated-meat-just-yet-says-ever-after-foods-were-not-offering-incremental-improvements-but-something-truly-disruptive
Dr. Michal Sheleg on a Novel Immunotherapy Platform for Solid Tumor Treatment
https://docwirenews.com/post/dr-michal-sheleg-on-a-novel-immunotherapy-platform-for-solid-tumor-treatment
New Immune Cell Patent !!!
IMO...PLURI BIOTECH WILL DOMINATE THE GLOBAL IMMUNE CELL EXPANSION MARKET !!!
Expanded To Many Types Of Immune Cells !!
Immune cells are one of Jurkat, T2 cells, K562 cells, Raji, U973, THP-1, HL-60, Peripheral Blood Mononuclear Cells (PBMC), polymorphonuclear cells (PMN), conventional and unconventional T cells, B cells, B cell Hybridomas, CAR-B, NKT cells, CAR-NKT, gamma-delta T (gdT), CAR-gdT, NK cells, CAR-NK, and combinations thereof. Said conventional or unconventional T-Cell immune cells are unmodified or modified T cells consisting of the group: CAR-T, CAR-MAIT, modified T cell receptor (TCR)-T, modified TCR-MAIT, TILs (Tumor Infiltrating Lymphocytes), and combinations thereof.
The method according to claim 18, further comprising a step of genetically modifying said population of immune cells inside said 3D bioreactor by adding to said fluid media one or more gene modifying agents capable of genetically modifying said population of immune cells suspended in said fluid media spiked into said fluid media.
https://patentscope.wipo.int/search/en/detail.jsf?docId=US431346161&_cid=P12-LXQ3ZQ-63878-1
Pluri: Biotech Play With Several Opportunities Across Different Sectors
https://seekingalpha.com/article/4699864-pluri-several-opportunities-across-different-sectors
After Doing More Research On Buhler AG, They Are Probably Not Making Ever After' Foods Bioreactors.
After Doing More Research On Buhler AG, They Are Probably Not Making Ever After' Foods Bioreactors.
Ever After Foods Sold Shares To: (CSFC Investments), Which Is Cargill Financial Service Corporation, As Well As To: Interfonda, A Part Of Buhler AG, The Company That Will Be Building Ever After Foods Bioreactors. Very Exciting News !!!
SHARE PURCHASE AGREEMENT
This Share Purchase Agreement (this “Agreement”) is entered into on June 12, 2024, by and among (i) Ever After Foods Ltd., a company incorporated in Israel, Reg. No. 516502556 with a registered address at M.T.M – Scientific Industries Centre, building 5, Haifa 3508409, Israel (formerly known as Plurinuva Ltd. - the “Company”), (ii) CFSC Investments, Inc., a Delaware corporation, with a principal mailing address at 15407 McGinty Road West, Wayzata, Minnesota 55391, United States (“CFSC”), (iii) Interfonda AG, a company incorporated in Switzerland, Reg. No. CHE-102.588.792 with a registered address at c/o [**], Gupfenstrasse 5, 9240 Uzwil, Switzerland (“Interfonda”), (iv) Tnuva Food-Tech Incubator (2019), Limited Partnership, Reg. No. 540287620 with a registered address at 21 Yagia Kapayim Street, Kiryat Arie, POB 300, Petah Tikva 4910201, Israel (“Tnuva”), (v) Pluri Biotech Ltd., a company incorporated in Israel, Reg. No. 513371666 with a registered address at M.T.M – Scientific Industries Centre, building 5, Haifa 3508409, Israel (“Pluri”, and together with CFSC, Interfonda, and Tnuva, the “Lead Investors”), and (vi) the other person(s) and/or entity(ies) listed in Exhibit A attached hereto, as may be updated from time to time (each of CFSC, Tnuva, Pluri, Interfonda, and such other person or entity, an “Investor”, and, severally and not jointly, the “Investors”) on the other side.
https://www.sec.gov/ix?doc=/Archives/edgar/data/1158780/000121390024053515/ea0207508-8k_pluri.htm
Pluri Subsidiary Ever After Foods Secured $10 Million Strategic Investment to Solve Cultivated Food Scalability Challenges
https://pluri-biotech.com/releases/pluri-subsidiary-ever-after-foods-secured-10-million-strategic-investment-to-solve-cultivated-food-scalability-challenges/
Pluri Subsidiary Ever After Foods Secured $10 Million Strategic Investment to Solve Cultivated Food Scalability Challenges
https://pluri-biotech.com/releases/pluri-subsidiary-ever-after-foods-secured-10-million-strategic-investment-to-solve-cultivated-food-scalability-challenges/
Pluri bags $1.4m to advance nuclear radiation therapy.
https://www.bioprocessintl.com/therapeutic-class/pluri-bags-1-4m-to-advance-nuclear-radiation-therapy